Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bioventus (BVS) Accumulated Expenses (2020 - 2025)

Bioventus' Accumulated Expenses history spans 6 years, with the latest figure at $130.2 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 4.15% year-over-year to $130.2 million; the TTM value through Dec 2025 reached $130.2 million, down 4.15%, while the annual FY2025 figure was $130.2 million, 4.15% down from the prior year.
  • Accumulated Expenses reached $130.2 million in Q4 2025 per BVS's latest filing, up from $119.4 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $146.8 million in Q3 2022 to a low of $89.7 million in Q2 2021.
  • Average Accumulated Expenses over 5 years is $119.7 million, with a median of $119.2 million recorded in 2023.
  • Peak YoY movement for Accumulated Expenses: soared 49.08% in 2021, then decreased 18.8% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $131.5 million in 2021, then decreased by 15.14% to $111.6 million in 2022, then grew by 7.37% to $119.8 million in 2023, then rose by 13.43% to $135.9 million in 2024, then dropped by 4.15% to $130.2 million in 2025.
  • Per Business Quant, the three most recent readings for BVS's Accumulated Expenses are $130.2 million (Q4 2025), $119.4 million (Q3 2025), and $113.7 million (Q2 2025).